Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells - Flourakis, M; Lehen'kyi, V; Beck, B; Raphaël, M; Vandenberghe, M; Abeele, F V; Roudbaraki, M; Lepage, G; Mauroy, B; Romanin, C; Shuba, Y; Skryma, R; et al. (Cell death & disease, 2010)
Keywords: 631/45/269/1146; 631/80/304; 631/80/82/23; 692/699/67/589/466; Amino Acid Substitution; Antibodies; Antineoplastic Agents - therapeutic use; Apoptosis; Biochemistry; Biomedical and Life Sciences; Calcium - metabolism; Calcium Channels - genetics; Calcium Channels - metabolism; Calcium Channels - physiology; Cell Biology; Cell Culture; Cell Line, Tumor; Cisplatin - therapeutic use; Humans; Immunology; Life Sciences; Male; Membrane Proteins - metabolism; Mutation; Neoplasm Proteins - metabolism; ORAI1 Protein; Original; original-article; Phenotype; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Stromal Interaction Molecule 1; Thapsigargin - therapeutic use; Tumor Necrosis Factor-alpha - therapeutic use; prostate cancer; apoptosis resistance; Orai channels; store-operated calcium entry